Drug Development Life Science Study 
Digital Health Global
JANUARY 28, 2025
a leading provider of clinical development technology, today announced 80% revenue growth in 2024 across enterprise customers adopting a SaaS model for portfolio-level electronic clinical outcomes assessment (eCOA) technology investments compared to study-by-study contracts. in DCT-enabled studies.
Healthcare IT Today
MARCH 3, 2025
The $55M in new funding will allow the company to further develop their AI technology and eClinical platform, Citrus, to optimize study design, automate central monitoring of study data, enable instant biostatistics, and more, as well as hiring in key areas including clinical operations and product development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digital Health Global
NOVEMBER 20, 2023
With long-term backing from AstraZeneca and strategic collaborations with Parexel and Fortrea, Evinova offers globally-scaled digital products and services to the life sciences and healthcare sector. However, they are vital to the drug development and approval process and critical in enabling access to innovative medicines.
Healthcare IT News - Telehealth
JANUARY 20, 2022
That is the opinion of Ron Emerson, RN, global healthcare lead at Zoom, as he looks ahead at what he believes will be some developments in healthcare in 2022. As illustrated in a 2019 study published in JAMA Internal Medicine , the percentage of adults in the United States with a primary care physician has been on the decline for years.
Healthcare IT Today
NOVEMBER 6, 2023
This strategic consolidation establishes PicnicHealth as the leading patient-centric evidence-generation partner within a rapidly evolving life sciences landscape. “AllStripes and PicnicHealth share a common vision of elevating clinical studies by putting patients at the core of the research experience. .
Lloyd Price
NOVEMBER 16, 2024
The new company aims to leverage its extensive data sets and technology to provide innovative solutions across various healthcare sectors, including life sciences, provider, imaging, health plan, employer, and government health and human services.
Digital Health Global
MARCH 29, 2023
With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drug development, patient care and new drug discovery,” said Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We
Expert insights. Personalized for you.
88 
Let's personalize your content